"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
The SIQ for this article will be revealed
marsupialization, subchordal cyst, delayed complication, hyaluronic acid, injection laryngoplasty
Nur Asyiqin Kamarudin, Norazila Abdul Rahim, Mawaddah Azman, Marina Mat Baki
Cite this article as: Kamarudin N, Abdul Rahim N, Azman M, et al. (August 08, 2022) Subchordal Cyst Containing Non-degraded Hyaluronic Acid: A Rare Complication of Injection Laryngoplasty. Cureus 14(8): e27801. doi:10.7759/cureus.27801
Injection laryngoplasty (IL) with hyaluronic acid (HA) for the treatment of glottic insufficiency has been reported as a safe procedure with low complication rates. The side effects usually present as acute dyspnea, dysphonia, or dysphagia due to local edema, hematoma, or hypersensitivity reactions. These complications commonly resolve with minimal intervention. In the present case, we present an asymptomatic case of a subchordal cyst (SC) in a 30-year-old female after office-based injection laryngoplasty using hyaluronic acid. To the best of our knowledge, this is the first reported case of a subchordal cyst following injection laryngoplasty.
Hyaluronic acid (HA) is a linear polysaccharide of glycosaminoglycan present in the lamina propria of the vocal fold extracellular matrix [1]. Its biocompatible, biodegradable, and viscoelastic properties [2] render HA suitable for use as a temporary injectate in injection laryngoplasty (IL). Unmodified HA has a half-life of approximately 24 hours [3]. Thus, for use as a dermal filler, HA is modified by crosslinking or conjugation to reduce its degradation rate [2]. IL using HA is safe, with a complication rate of just 3.8%-4.7%, mainly due to local hypersensitivity and inflammation [1]. In a systematic review of 14 studies, only two adverse effects were described: vocal fold hematoma and aryepiglottic fold edema [1]. Here, we present a case of subchordal cyst (SC) formation following IL using HA.
A 30-year-old female underwent hemithyroidectomy for a left multinodular goiter where the recurrent laryngeal nerve was preserved. However, she experienced hoarseness, voice fatigue, and dysphagia with liquids including concern for aspiration with drinking fluids following the surgery for one month prior to referral to our center. Her voice-related quality of life as measured using the Malay version of the Voice Handicap Index-10 (mVHI-10) [4] was 34/40, indicating severe voice-related handicap. The score for Eating Assessment Tool (EAT-10) was abnormal, which was 13. The perceptual evaluation of her voice using the overall grade of dysphonia, roughness, breathiness, asthenia, and strain (GRBAS) scale [5] showed a severe deviation of voice with the main component of breathiness and asthenia (G3R0B3A3S1). Furthermore, her maximum phonation time was shortened to three seconds. Video laryngoscopy revealed a bowed and immobile left vocal fold in the lateral position with a large phonatory gap (Figure 1) (Video 1).
Videostroboscopy revealed an asymmetrical mucosal wave with a decrease in amplitude on the left vocal fold (Video 2).
IL was performed in a clinical setting under local anesthesia. HA (Juvéderm Ultra XC, Allergan, USA) was injected into the left paraglottic space lateral to the left vocal fold via the trans-thyrohyoid approach using a double-bend needle [6]. It was confirmed that the injectates has not passed the expiry date prior to the procedure. The follow-up appointment was delayed due to COVID-19-related restrictions. At three months post-injection, her voice returned to normal (mVHI-10 score of 2/40). Video laryngoscopy revealed return of left vocal fold mobility. However, there was a smooth translucent swelling seen in the left subglottic region with no airway obstruction (Figure 2).
The swelling remained the same for 20 months post-IL. Contrast-enhanced computed tomography (CECT) scan of the neck showed a non-enhancing, well-defined, hypodense lesion arising in the left side of the subglottic region (0.8 × 0.4 × 0.8 cm) (Figure 3).
A diagnosis of acquired subchordal cyst secondary to IL was made.
The patient underwent marsupialization of the cyst under general anesthesia with tubeless ventilation in which the larynx was visualized and suspended using a rigid subglottic laryngoscope. The cyst was found to be located in the subglottic region adjacent to the inferior surface of the left vocal fold (Figure 4).
Upon marsupialization, gel-like material resembling HA was observed (Figure 5) (Video 3).
Histopathological evaluation of the SC wall showed amorphous material positive for Alcian blue and negative for periodic acid-Schiff stain with surrounding foreign body reaction suggesting exogenous HA.
The patient was reviewed in the clinic two weeks post-marsupialization. Her voice was normal, and videostroboscopy revealed normal vocal folds with a symmetrical mucosal wave.
HA can bind to 1,000 times its weight in water. Following injection into the tissue, it will absorb water and slowly expand within 24 hours [3]. This delayed swelling may explain why the SC was not observed earlier during the procedure. Initially, we postulated that the SC was formed due to the mechanical obstruction of the ductal systems draining the seromucinous glands of the vocal fold, which lead to a collection of mucus-filled cavities lined by the epithelium. However, the intraoperative findings and histopathology results clearly indicated the cyst to contain exogenous HA.
In vivo, 70% of HA is catabolized systemically, where it is transported via the lymphatic or blood vessels to the lymph node or liver, respectively. It is then internalized and catabolized by endothelial cells. The remaining 30% is degraded locally by hyaluronidase or oxidative damage by reactive oxygen species [2]. Thus, mechanical compression of the lymphatic and vascular supply by HA may explain why it was not degraded in our patient. Furthermore, the utilized HA (Juvéderm Ultra XC) is more resistant to hyaluronidase degradation when compared with the Restylane family [7]. HA fillers differ in their cohesivity, viscosity, and response to hyaluronidase. This variation depends on the extent of the crosslinking, concentration, particulate size, and mono- or biphasic status. The monophasic form (cohesive gel without particles) is more resistant to hyaluronidase because biphasic filler (particles suspended in gel) has a greater surface area for enzymatic attack. Both factors, being monophasic with higher crosslinking and higher HA concentrations may explain why Juvéderm is more resistant to resorption and degradation [7].
In our setting, IL was done percutaneously under flexible endoscopic laryngoscopy guidance. The HA is aimed to be injected into the paraglottic space. However, even under laryngoscopy guidance, the tip of the needle still cannot be seen clearly, resulting in the risk of the material being injected either too superficial or too deep. Thus, another possibility for the development of SC in this case was that the tip of the needle went beyond the conus elasticus and was injected submucosally at the inferior surface of the vocal fold. To overcome this problem, Wang et al. have suggested performing IL under laryngeal electromyography (LEMG) guided to ensure accurate infiltration of the material at the thyroarytenoid and lateral cricoarytenoid complex [1].
HA has been known to be biodegradable, where it typically lasts for 4-6 months, with beneficial outcomes seen up to 12 months post-IL [1]. To the best of our knowledge, this is the first case described in the literature of SC containing non-degradable HA secondary to IL.
SC is a rare complication following IL using HA. Routine follow-up is crucial given the possibility of delayed complications following IL. This report suggests that HA may persist for at least 20 months without degradation following IL. Management of the SC containing non-degraded HA with marsupialization showed a good outcome with complete resolution and no adverse sequelae.
Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, MYS
Department of Otorhinolaryngology, Faculty of Medicine, Universiti Teknologi MARA (UiTM), Puncak Alam, MYS
Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, MYS
Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, MYS
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Kamarudin N, Abdul Rahim N, Azman M, et al. (August 08, 2022) Subchordal Cyst Containing Non-degraded Hyaluronic Acid: A Rare Complication of Injection Laryngoplasty. Cureus 14(8): e27801. doi:10.7759/cureus.27801
Peer review began: July 14, 2022 Peer review concluded: August 07, 2022 Published: August 08, 2022
© Copyright 2022 Kamarudin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.
This link will take you to a third party website that is not affiliated with Cureus, Inc. Please note that Cureus is not responsible for any content or activities contained within our partner or affiliate websites.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
High ratings should be reserved for work that is truly groundbreaking in its respective field. Anything above 5 should be considered above average. While all registered Cureus users can rate any published article, the opinion of domain experts is weighted appreciably more than that of non-specialists. An article’s SIQ™ will appear alongside the article after being rated twice and is recalculated with each additional rating.
Visit our SIQ™ page to find out more.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
Already have an account? Sign in.
Please note that by doing so you agree to be added to our monthly email newsletter distribution list.
By joining Cureus, you agree to our Privacy Policy and Terms of Use.